Crizotinib is a class Ia small molecule dual inhibitor of c-Met and anaplastic lymphoma kinase (ALK) that was approved for therapeutic use in advanced non-small cell lung cancers positive for either c-ros oncogene 1 (ROS-1) or ALK. Here, ALK is linked to non-small cell lung carcinoma.